Novo Nordisk Utilizes Gefion AI Supercomputer for Drug Discovery
Novo Nordisk has entered into a multiyear agreement with DCAI to utilize the Gefion AI supercomputer, as announced in a press release. This collaboration aims to enhance drug discovery and healthcare innovation by harnessing Gefion's advanced computational capabilities.
The agreement allows Novo Nordisk to access Gefion's NVIDIA DGX SuperPod technology, which is expected to accelerate the development of new therapies by processing vast datasets. This initiative is part of Novo Nordisk's strategic focus on integrating AI across its value chain.
Gefion, ranked 21st on the Top500 list of supercomputers, will support Novo Nordisk in tackling compute-heavy challenges such as AI-based protein engineering and biological modeling. The partnership also includes collaboration with NVIDIA to develop customized models for early research and discovery.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Danaher and NVIDIA Bring AI Into Laboratory Instruments
Hansa Biopharma Partners With Cradle on AI Protein Design
CAS and Novartis Partner on Reaction Data for AI Research
NVIDIA Plans Investments in Four French Startups
AbbVie Partners With Valkai on AI Tools for Clinical Development
Daily AI Brief: the AI news that matters, in your inbox.